Evidence map›Paper›PMID 22446105›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2012

Squelching of ETS2 transactivation by POU5F1 silences the human chorionic gonadotropin CGA subunit gene in human choriocarcinoma and embryonic stem cells.

Rangan Gupta, Toshihiko Ezashi, R Michael Roberts

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Transcriptional control ofReproduction (Cambridge, England) · 2017
    Review
  4. Article
  5. Article
  6. Comparison of syncytiotrophoblast generated from human embryonic stem cells and from term placentas.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rangan GuptaDepartment of Veterinary Pathobiology, Bond Life Sciences Center, University of Missouri, Columbia, Missouri 65211, USA.
Toshihiko Ezashi
R Michael Roberts
University of Missouri · US

Funding

INTERACTION BETWEEN BLASTOCYST AND UTERINE ENDOMETRIUMR01HD021896 · NICHD · UNIVERSITY OF MISSOURI-COLUMBIA · PI ROBERTS, R. MICHAEL · 1986 to 2010
$2.8M
Pluripotent human stem cells as models for normal and diseased trophoblastR01HD067759 · NICHD · UNIVERSITY OF MISSOURI-COLUMBIA · PI ROBERTS, R. MICHAEL · 2011 to 2015
$1.7M
INTERACTION BETWEEN BLASTOCYST AND UTERINE ENDOMETRIUMR37HD021896 · NICHD · UNIVERSITY OF MISSOURI-COLUMBIA · PI ROBERTS, ROBERT MICHAEL · 1990 to 1999
–
NICHD NIH HHS HD067759NICHD NIH HHS HD21896NICHD NIH HHS R01 HD021896NICHD NIH HHS R01 HD067759NICHD NIH HHS R37 HD021896
6 · The paper itself

Abstract

The subunit genes encoding human chorionic gonadotropin, CGA, and CGB, are up-regulated in human trophoblast. However, they are effectively silenced in choriocarcinoma cells by ectopically expressed POU domain class 5 transcription factor 1 (POU5F1). Here we show that POU5F1 represses activity of the CGA promoter through its interactions with ETS2, a transcription factor required for both placental development and human chorionic gonadotropin subunit gene expression, by forming a complex that precludes ETS2 from interacting with the CGA promoter. Mutation of a POU5F1 binding site proximal to the ETS2 binding site does not alter the ability of POU5F1 to act as a repressor but causes a drop in basal promoter activity due to overlap with the binding site for DLX3. DLX3 has only a modest ability to raise basal CGA promoter activity, but its coexpression with ETS2 can up-regulate it 100-fold or more. The two factors form a complex, and both must bind to the promoter for the combination to be transcriptionally effective, a synergy compromised by POU5F1. Similarly, in human embryonic stem cells, which express ETS2 but not CGA, ETS2 does not occupy its binding site on the CGA promoter but is found instead as a soluble complex with POU5F1. When human embryonic stem cells differentiate in response to bone morphogenetic protein-4 and concentrations of POU5F1 fall and hCG and DLX3 rise, ETS2 then occupies its binding site on the CGA promoter. Hence, a squelching mechanism underpins the transcriptional silencing of CGA by POU5F1 and could have general relevance to how pluripotency is maintained and how the trophoblast lineage emerges from pluripotent precursor cells.

Indexed as

Gene SilencingTranscriptional ActivationBone Morphogenetic Protein 4Cell DifferentiationCell LineChoriocarcinomaChorionic Gonadotropin, beta Subunit, HumanEmbryonic Stem CellsFemaleGlycoprotein Hormones, alpha SubunitHomeodomain ProteinsHumansMutationNeoplasm ProteinsOctamer Transcription Factor-3PregnancyBMP4 protein, humanBone Morphogenetic Protein 4CGA protein, humanChorionic Gonadotropin, beta Subunit, HumanDistal-less homeobox proteinsETS2 protein, humanGlycoprotein Hormones, alpha SubunitHomeodomain ProteinsNeoplasm ProteinsOctamer Transcription Factor-3POU5F1 protein, humanProto-Oncogene Protein c-ets-2Recombinant ProteinsTranscription Factors

Identifiers

PMID22446105
PMCPMC3355552
OpenAlexW2022873055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.